Underdogs in the Stock Market

Celebrities tend to attract a lot of media attention, but the real future stars of the market often start as underdogs, lurking in the shadows. Think of Wall Street as a kind of “magnificent seven.” Some of the most promising opportunities can be found in stocks priced under $5.

This is where your investment journey commences:

These low-cost securities are known as penny stocks, and they can sometimes show impressive growth potential. Whether it’s thanks to a game-changing innovation or a disruptive product, the right catalyst can lead to significant gains.

However, it’s crucial to remember that not all penny stocks have hidden value. Some are stuck at the bottom for valid reasons, often due to overwhelming challenges that might be too complex to overcome.

So, how do you pinpoint the ones that could soar? That’s where Wall Street analysts come into play.

Utilizing Tipranks’ database, we’ve highlighted two promising penny stocks that analysts rate highly. Both have a consensus rating of “strong buy” and show considerable potential for growth. Let’s take a closer look.

Skye Bioscience (Skye)

First up is Skye Bioscience, a biopharmaceutical company focused on developing treatments for metabolic disorders, particularly obesity. This is a promising area for innovative biotech firms. The global market for anti-obesity drugs is expected to surge from $12.8 billion in 2025 to around $104.9 billion by 2035, reflecting a compound annual growth rate of 21.1%. Beyond its prevalence, obesity is linked to numerous physical and mental health issues, thereby creating a strong demand for effective treatment.

In response, Skye is taking a unique approach to weight loss by selectively inhibiting the CB1 pathway. Their lead candidate, nimashimab, is specifically designed to avoid central nervous system side effects encountered by earlier CB1-targeted drugs. Currently, nimashimab is nearing a pivotal Phase 2A clinical trial, with top-line data expected in late 2024 or early 2025.

In preliminary phases, it displayed encouraging results. In an April update, Skye noted that in a mouse model, combining nimashimab with tilzepatide (a dual GLP-1/GIP agonist) led to over 30% weight loss in just 25 days. Nimasimab alone resulted in a 23.5% reduction, comparable to using tilzepatide or monperabant alone. Importantly, safety reviews by the Data Safety Monitoring Committee have raised no concerns to date.

Looking forward, Skye is collaborating with Arecor Therapeutics to explore new formulations of nimashimab. Under this partnership, Skye aims to leverage Arecor’s proprietary platform for development while retaining rights for future licensing and commercialization.

With Skye trading at $2.16, JMP analyst Jonathan Wolleben sees a significant opportunity, especially with crucial data releases approaching.

“We continue to favor nimashimab’s position in the CB1 inhibitor landscape. Patient interest seems strong for differentiated mechanisms in the obesity space. Skye’s history shows it hasn’t encountered adverse neuropsychiatric effects in earlier trials,” Wolleben expressed.

On a bullish note, Wolleben has set a price target of $16 for Skye, predicting a dramatic upside potential of 594% within a year.

The overall sentiment for Skye is even more optimistic, with a unanimous “strong buy” consensus from six analysts contributing to an average price target of $17.20. This suggests a staggering upside of 696% over the next year.

Polypide (PYPD)

Surgery can be really tough for patients, dealing with infection, inflammation, and pain among other complications. Polypid, a clinical-stage biopharmaceutical company, is working to tackle these issues through enhanced drug delivery methods.

They’ve developed a unique drug delivery system named Plex, which enables targeted, sustained release of post-operative medications. Made from layers of alternating polymers and lipids, this system can effectively deliver various therapeutic agents while minimizing toxicity, ensuring long-term efficacy.

Polypid’s lead product candidate, D-Plex100, is currently undergoing evaluation in two Phase 3 trials, Shield I and Shield II, specifically aimed at preventing surgical site infections post-abdominal colorectal surgery.

While Shield I didn’t meet its primary goals, earlier this month, Polypid announced positive outcomes from Shield II. This study successfully achieved both primary and secondary objectives, demonstrating statistically significant benefits for 798 patients undergoing major abdominal surgeries. These results allow the company to gear up for a potential new drug application (NDA) submission in early 2026 while paving the way for global partnership discussions.

To bolster future prospects, Polypid secured up to $26.7 million in funding and extended its cash runway through potential FDA approval for D-Plex100.

Roth Capital Analyst Boobalan Pachaiyappan views the Shield II results as a turning point. They not only confirm clinical effectiveness but also outline a clear path toward regulatory approval and substantial market prospects for D-Plex100.

“D-PLEX100 showed broad efficacy across all secondary endpoints. While comprehensive safety data isn’t available yet, topline results suggest a favorable safety profile consistent with earlier studies, making it suitable for surgical site infection treatment,” Pachaiyappan noted.

He has set a $9 price target, indicating a 174% increase potential within a year.

In total, five recent analyst assessments for PYPD show a strong buy consensus, with four recommendations to buy against one hold. The current price stands at $3.28, with an estimated target of $11.50, suggesting a remarkable 250% rise in the next year.